Akari Therapeutics, Plc
AKTX
$0.925
-$0.0249-2.62%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -9.59% | -11.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.52% | -17.93% | |||
| Operating Income | 11.52% | 17.93% | |||
| Income Before Tax | 48.85% | 1.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 48.85% | 1.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 48.85% | 1.78% | |||
| EBIT | 11.52% | 17.93% | |||
| EBITDA | 11.53% | 17.99% | |||
| EPS Basic | 55.64% | 30.20% | |||
| Normalized Basic EPS | 28.80% | 4.12% | |||
| EPS Diluted | 55.64% | 30.20% | |||
| Normalized Diluted EPS | 28.80% | 4.12% | |||
| Average Basic Shares Outstanding | 15.31% | 40.63% | |||
| Average Diluted Shares Outstanding | 15.44% | 40.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||